Rani Therapeutics Holdings, Inc.
RANI
$1.38
-$0.01-0.62%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -28.27% | -21.98% | -12.92% | -6.28% | -15.19% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -38.49% | -16.12% | -13.18% | -8.65% | -33.92% |
| Operating Income | 38.49% | 16.12% | 14.40% | 16.30% | 33.92% |
| Income Before Tax | 37.79% | 15.99% | 13.81% | -11.86% | 30.60% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 37.79% | 15.99% | 13.81% | -11.86% | 30.60% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -57.87% | -30.87% | -24.97% | -2.62% | -34.99% |
| Net Income | 20.21% | 1.66% | 2.93% | -26.05% | 26.25% |
| EBIT | 38.49% | 16.12% | 14.40% | 16.30% | 33.92% |
| EBITDA | 39.05% | 16.33% | 14.68% | 16.88% | 34.57% |
| EPS Basic | 50.47% | 29.17% | 24.43% | 0.15% | 34.65% |
| Normalized Basic EPS | 24.64% | 0.44% | 0.27% | 68.27% | 23.21% |
| EPS Diluted | 50.47% | 29.17% | 24.43% | 0.15% | 34.65% |
| Normalized Diluted EPS | 24.64% | 0.44% | 0.27% | 68.27% | 23.21% |
| Average Basic Shares Outstanding | 61.06% | 38.82% | 28.45% | 26.23% | 12.85% |
| Average Diluted Shares Outstanding | 61.06% | 38.82% | 28.45% | 26.23% | 12.85% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |